InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,063.79
(
-0.28%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: None

Monday, 06/07/2010 6:13:59 PM

Monday, June 07, 2010 6:13:59 PM

Post# of 80490
Updated slides from today's ASCO presentation are available for download. Slide 9 shows a 58% MCyR for pts in the 30mg or higher cohort. This data indicates AP534 is more effective than either Tasigna or Sprycel even though the AP534 trial included a more resistant patient population than that enrolled in either the Tasigna or Sprycel trials.

http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-IRHome
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up